DrugRisk Update: Court Issues Latest Data In Pradaxa Lawsuits

The DrugRisk Center is the largest source on the Web for information on prescription drug research, side effects and legal news. Visit http://www.DrugRisk.com

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
Pradaxa Diagram
Recently, the FDA launched a new study comparing the rates of internal bleeding and blood clots for patients taking Pradaxa and warfarin.

Chicago, IL (PRWEB) February 28, 2014

The prescription drug safety advocates at DrugRisk.com are announcing updated legal news on the site for patients taking the blood thinner Pradaxa. Recent court records show the number of lawsuits alleging the drug caused internal bleeding have risen since January*.

DrugRisk was created to give those taking popular prescription drugs the latest recalls, safety alerts, research and litigation news. Visitors can see if others are experiencing similar side effects, avoid potential dangers and decide if they need legal advice.

Pradaxa is prescribed to prevent blood clots and strokes in patients with atrial fibrillation. Experts disagree, however, whether it increases risks of internal bleeding.

DrugRisk has added a study suggesting patients taking newer blood thinners like dabigatran may be 55% more likely to suffer internal bleeding**. The Institute for Safe Medication Practices has also advised internal bleeding from Pradaxa could be 5 times as likely to cause death***.

Recently, the FDA launched a new study comparing the rates of internal bleeding and blood clots for patients taking Pradaxa and warfarin****. A report also alleges Boehringer failed to inform the agency of an analysis showing higher-than-expected patient bleeding deaths from Pradaxa*****.

Due to the number of families filing a Pradaxa lawsuit alleging internal bleeding, cases have been consolidated in a special federal Pradaxa multidistrict litigation court. The case is formally known as MDL No. 2385, IN RE: Pradaxa Product Liability Litigation, Southern District of Illinois.

Now, DrugRisk has learned the latest update from the court shows 2,139 cases pending for February alleging internal bleeding, up nearly 4% since January 15*.

Anyone who suffered internal bleeding after taking Pradaxa is encouraged to visit DrugRisk.com or speak with a lawyer about their legal options. Due to the specialized nature of federal drug injury cases, DrugRisk only recommends lawyers who have already handled Pradaxa lawsuits.

Visit http://www.DrugRisk.com today for more information on the research, side effects and litigation news related to Pradaxa and other drugs, or to speak with a lawyer.

*JPML, 2/19/14; jpml.uscourts.gov/sites/jpml/files/Pending_MDL_Dockets_By_District-February-19-2014.pdf
**Gastroenterology, July 2013; gastrojournal.org/article/S0016-5085(13)00290-4/fulltext
***Institute for Safe Medication Practices, 1/9/13; ismp.org/quarterwatch/pdfs/2012Q2.pdf
****Forbes, 1/3/14; forbes.com/sites/larryhusten/2014/01/03/fda-plans-new-safety-assessment-of-dabigatran-pradaxa/
*****Bloomberg, 2/26/14; bloomberg.com/news/2014-02-25/boehringer-kept-pradaxa-analysis-from-fda-records-show.html


Contact